Skip to main content
Premium Trial:

Request an Annual Quote

Cynvenio Signs International Distribution Agreements for Liquid Biopsy Tests

NEW YORK (GenomeWeb) – Cynvenio Biosystems said today that it has signed four new distribution agreements for its ClearID line of liquid biopsy tests, making the assays available immediately for patients in Israel, Greece, Argentina, and South Korea.

Pronto Diagnostics will market ClearID in Israel, Karyo in Greece, ProgeniTest in Argentina, and Bio-Medical Science in South Korea.

Cynvenio will continue to perform the tests in its CLIA lab for now. But the company's CEO André de Fusco said that in the future, labs may be able to install the firm's automated liquid biopsy platforms in their own facilities.

The ClearID tests, which detect cancer-associated mutations in both circulating tumor cells and circulating cell-free DNA, are designed for cancer patients undergoing treatment and those who require follow-up testing at regular intervals after completion of therapy. The menu includes separate sequencing panels optimized for breast, colon, and lung cancer.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.